# Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

> **NCT06599619** · — · RECRUITING · sponsor: **John Kirkwood** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Single agent, adjuvant anti-PD1 therapy

## Key facts

- **NCT ID:** NCT06599619
- **Lead sponsor:** John Kirkwood
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2029-05
- **Final completion:** 2029-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06599619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06599619, "Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06599619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*